Sep 28, 2009 by Brian Orelli, PhDAbbott Labs Looks Less LopsidedThe pharma scores a nice medium-sized pickup.
Sep 28, 2009 by Brian Orelli, PhDHere We Go Again With Possible Side EffectsMerck is the newest victim.
Sep 25, 2009 by Brian Orelli, PhDDendreon Struts Its StuffLike a peacock without any FDA-approved feathers.
Sep 25, 2009 by Brian Orelli, PhDOh, No! Another Tylenol Recall?Take a deep breath. Everything will be OK.
Sep 24, 2009 by Brian Orelli, PhDDrugmakers' HIV Treatments Live OnA vaccine doesn't look like an imminent threat to revenue.
Sep 23, 2009 by Brian Orelli, PhDWitch Hunt, Round 2?Humana mails Medicare Advantage members, and not everyone approves. Either way, somebody has some chutzpah.
Sep 23, 2009 by Brian Orelli, PhDNexavar, and Onyx, Nail ItSolid data. Now let's see how phase 3 turns out.
Sep 22, 2009 by Brian Orelli, PhDPfizer and Wyeth Put the Horse Before the CartThe pharmas' animal-business divestiture brings them one step closer to unity.
Sep 21, 2009 by Brian Orelli, PhDThe Biggest Market Opportunity: Health-Care Stalemate?If it happens, here's how to play it.
Sep 18, 2009 by Brian Orelli, PhDHey, Sequenom, That's Great, But ...Investors are still waiting for the real news from Sequenom.
Sep 18, 2009 by Brian Orelli, PhDA 25% Stock Gain Will Ease Any PainGlaxo and XenoPort's shingles drug gives the latter's shares a healthy boost.
